PubRank

Mary L Disis

Author PubWeight™ 120.34‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 22.96
2 Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother 2002 2.65
3 Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol 2011 2.52
4 Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res 2011 2.44
5 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
6 Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol 2005 2.31
7 Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009 1.98
8 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
9 Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006 1.65
10 Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol 2008 1.60
11 Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008 1.59
12 Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med 2010 1.57
13 IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol 2006 1.53
14 Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002 1.51
15 Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004 1.49
16 CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother 2006 1.47
17 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
18 Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006 1.31
19 TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol 2011 1.30
20 Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol 2010 1.26
21 VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2011 1.25
22 Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res 2008 1.24
23 The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res 2006 1.22
24 The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2007 1.21
25 Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res 2010 1.20
26 Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res 2003 1.19
27 Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 2008 1.15
28 Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) 2012 1.15
29 Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005 1.14
30 Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials 2010 1.14
31 Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol 2007 1.14
32 Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood 2007 1.14
33 Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res 2006 1.04
34 ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines 2011 1.04
35 Conflicts of interest in translational research. J Transl Med 2004 1.03
36 Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano 2012 1.03
37 SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011 1.02
38 Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 2007 1.01
39 TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res 2011 1.00
40 Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res 2008 1.00
41 HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother 2010 0.99
42 Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods 2005 0.95
43 Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat 2005 0.95
44 Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 2004 0.95
45 Expanding assessments of translational research programs: supplementing metrics with value judgments. Eval Health Prof 2013 0.94
46 Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol 2007 0.93
47 The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila) 2013 0.92
48 Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines 2007 0.91
49 Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res 2012 0.91
50 Adoptive T cell therapy of solid cancers. Cancer Immunol Immunother 2005 0.89
51 Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces 2008 0.89
52 Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 2003 0.89
53 Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am 2003 0.89
54 Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions. Cancer Prev Res (Phila) 2013 0.88
55 Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol 2003 0.88
56 An analytical workflow for investigating cytokine profiles. Cytometry A 2008 0.87
57 Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007 0.86
58 Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers. Genes Chromosomes Cancer 2006 0.85
59 Adoptive T-cell therapy for the treatment of solid tumours. Expert Opin Biol Ther 2002 0.85
60 Phase I studies of drug combinations. J Clin Oncol 2010 0.85
61 An HLA-DR-degenerate epitope pool detects insulin-like growth factor binding protein 2-specific immunity in patients with cancer. Cancer Res 2008 0.85
62 Tumor stromal barriers to the success of adoptive T cell therapy. Cancer Immunol Immunother 2007 0.84
63 Three-dimensional scaffolds to evaluate tumor associated fibroblast-mediated suppression of breast tumor specific T cells. Biomacromolecules 2013 0.84
64 Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept. OMICS 2011 0.83
65 Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells. J Clin Immunol 2005 0.83
66 T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity. Breast Cancer Res Treat 2013 0.83
67 His-tag ELISA for the detection of humoral tumor-specific immunity. BMC Immunol 2008 0.83
68 A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res 2010 0.82
69 Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 2008 0.81
70 Protein-bound polysaccharide activates dendritic cells and enhances OVA-specific T cell response as vaccine adjuvant. Immunobiology 2013 0.81
71 Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J Clin Oncol 2005 0.81
72 Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia. Am J Hematol 2003 0.81
73 Global role of the immune system in identifying cancer initiation and limiting disease progression. J Clin Oncol 2005 0.80
74 Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells. BMC Cancer 2005 0.80
75 Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer. Ann N Y Acad Sci 2009 0.80
76 Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses. BMC Immunol 2007 0.79
77 Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat 2014 0.79
78 CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer. Anticancer Agents Med Chem 2014 0.79
79 Immune modulation as a therapeutic strategy for non-small-cell lung cancer. Clin Lung Cancer 2008 0.78
80 Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol 2002 0.78
81 Therapeutic vaccines for ovarian cancer. Gynecol Oncol 2013 0.78
82 Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 2003 0.78
83 Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion. Mol Cancer Ther 2006 0.77
84 Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. Cancer Immunol Immunother 2009 0.77
85 Designing vaccines to prevent breast cancer recurrence or invasive disease. Immunotherapy 2015 0.76
86 Values in translation: how asking the right questions can move translational science toward greater health impact. Clin Transl Sci 2012 0.76
87 Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy. Proteomics Clin Appl 2013 0.76
88 Natural history of tumor growth and immune modulation in common spontaneous murine mammary tumor models. Breast Cancer Res Treat 2014 0.76
89 Molecular targeting with cancer vaccines. J Clin Oncol 2005 0.76
90 Adjuvant Oophorectomy in the Treatment of Early-Stage BRCA Mutation-Positive Breast Cancer. JAMA Oncol 2015 0.75
91 Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK. Cancer Immunol Immunother 2013 0.75
92 Underlying Autoimmune Disease Is Not a Contraindication to the Use of Ipilimumab. JAMA Oncol 2016 0.75
93 Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients. Breast Cancer Res Treat 2002 0.75
94 Immunotherapy of glioblastoma multiforme. Expert Rev Neurother 2003 0.75
95 Immunotherapy for breast cancer. Cancer Chemother Biol Response Modif 2002 0.75
96 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res 2006 0.75